Objective:To investigate the expression level of B3GNT5 in gastric cancer(GC)tissues and its correlation with clinicopathological parameters and patient prognosis.Methods:The expression difference of B3GNT5 in GC tissues versus adja-cent non-tumor tissues was analyzed using the GEPIA2 database,Kaplan-Meier Plotter database,and TCGA database.Its corre-lation with patient survival was also explored.Tissue samples and clinical data were collected from 85 GC patients.Immunohis-tochemistry(IHC)was used to detect B3GNT5 expression differences between GC tissues and adjacent non-tumor tissues.The correlation between B3GNT5 expression level and the clinicopathological characteristics of GC was analyzed.Results:Bioinfor-matics analysis showed that B3GNT5 was highly expressed in GC tissues and lowly expressed in adjacent non-tumor tissues,with a statistically significant difference(P<0.05).High expression of B3GNT5 was associated with poorer overall survival(OS)and recurrence-free survival(RFS)in GC patients(P<0.05).Pathological IHC revealed that B3GNT5 expression level was higher in GC tissues compared to adjacent non-tumor tissues.B3GNT5 expression level showed correlations with tumor in-vasion depth,lymph node,and TNM stagemetastasis(P<0.05).Kaplan-Meier survival analysis and Cox regression model a-nalysis indicated that B3GNT5 was an independent risk factor for prognosis assessment in GC(P<0.05).Conclusion:High ex-pression of B3GNT5 in gastric cancer is associated with poor prognosis and may serve as a potential biomarker for prognostic assessment in GC.